


Please type a plus sign (+) inside this box →



GAU 1645
HSP
1228-02
K. Schmitt

PTO/SB/21 (08-00)



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/081,119	
		Filing Date	February 21, 2002	
		First Named Inventor	REINHARD, CHRISTOPH	
		Group Art Unit	1645	
		Examiner Name		
Total Number of Pages in This Submission		3	Attorney Docket Number	2300-16932
ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group		
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences		
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information		
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter		
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):		
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address	1. Form PTO/SB/08A		
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer	2. Copy of 11 cited references		
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> Request for Refund	3. Return Receipt Postcard		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> CD, Number of CD(s) _____			
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm or Individual Name	JAMES S. KEDDIE, PH.D., Reg. No. 48,920			
Signature				
Date	July 1, 2002			

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: July 1, 2002.			
Typed or printed name	Susan M. Alessi		
Signature		Date	July 1, 2002

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Susan M. Alessi		
Signature	<i>Susan M. Alessi</i>	Date	July 1, 2002
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket	2300-16932	
	First Named Inventor	REINHARD, CHRISTOPH	
	Application Number	10/081,119	
	Confirmation No.		
	Filing Date	February 21, 2002	
	Group Art Unit	1645	
	Examiner Name		
Title: "TTK IN DIAGNOSIS AND AS A THERAPEUTIC TARGET IN CANCER"			

RECEIVED

JUL 15 2002
TECH CENTER 1600/2900

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. 2300-16932 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 1, 2002

By: *James S. Keddie*
James S. Keddie, Ph.D.
Registration No. 48,920

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/081,119
		Filing Date	February 21, 2002
		First Named Inventor	Reinhard, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	2300-16932	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CAHILL, et al. "Characterization of <i>MAD2B</i> and other mitotic spindle checkpoint genes", <i>Genomics</i> , (1999) Vol. 58(2): 181-187.	
		GENBANK Accession No. M86699	
		HANAHAN, et al. "The hallmarks of cancer", <i>Cell</i> , (2000) Vol. 100: 57-70.	
		HARUKI, et al. "Molecular analysis of the mitotic checkpoint genes <i>BUB1</i> , <i>BUBR1</i> , and <i>BUB3</i> in human lung cancers", <i>Cancer Letters</i> , (2001) Vol. 162: 201-205.	
		HOGG, et al. "Cell cycle dependent regulation of the protein kinase TTK", <i>Oncogene</i> , (1994) Vol. 9: 89-96.	
		MILLS, et al. "Expression of TTK, a novel human protein kinase, is associated with cell proliferation", <i>J. Biol. Chem.</i> , (1992) Vol. 267: 16000-16006.	
		MIMORI, et al. <i>Oncol. Rep.</i> , (2001) Vol. 8: 39-42.	
		OLESEN, et al. "Mitotic checkpoint genes <i>hBUB1</i> , <i>hBUB1B</i> , <i>hBUB3</i> , and <i>TTK</i> in human bladder cancer, screening for mutations and loss of heterozygosity", <i>Carcinogenesis</i> , (2001) Vol. 22(5): 813-815.	
		SAFFERY, et al. "Components of the human spindle checkpoint control mechanism localize specifically to the active centromere on dicentric chromosomes", <i>Hum. Genet.</i> , (2000) Vol. 107: 376-384.	
		SCHMANDT, et al. "IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression", <i>J. Immunol.</i> , (1994) Vol. 152: 96-105.	
		TOMIZAWA, et al. "Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau", <i>FEBS</i> , (2001) Vol. 492: 221-227.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (SB)